MARKET

VERU

VERU

Veru
NASDAQ
0.5554
-0.0257
-4.42%
After Hours: 0.5670 +0.0116 +2.09% 19:26 02/07 EST
OPEN
0.5950
PREV CLOSE
0.5811
HIGH
0.6000
LOW
0.5428
VOLUME
3.16M
TURNOVER
--
52 WEEK HIGH
1.920
52 WEEK LOW
0.3612
MARKET CAP
81.30M
P/E (TTM)
-1.9814
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VERU last week (0127-0131)?
Weekly Report · 6d ago
Largest borrow rate increases among liquid names
TipRanks · 01/30 13:45
Veru Inc.’s Promising Phase IIb Results Suggest Investment Opportunity with Enobosarm’s Weight Management Potential
TipRanks · 01/28 03:25
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher
Benzinga · 01/27 18:56
Dow Edges Higher; AT&T Posts Upbeat Earnings
Benzinga · 01/27 17:05
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Benzinga · 01/27 15:34
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December
Benzinga · 01/27 14:43
Veru down 46% despite data for drug preserving lean body mass in Wegovy users
Seeking Alpha · 01/27 14:35
More
About VERU
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.

Webull offers Veru Inc stock information, including NASDAQ: VERU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VERU stock methods without spending real money on the virtual paper trading platform.